We’re excited to share that MantaBio has raised $2.5 million in seed funding to accelerate development of our automated platform for microbial contamination detection in biologics manufacturing.
Biologics represent one of the fastest-growing and most valuable segments in pharmaceuticals, generating over $400 billion annually. Yet despite decades of progress, most biopharma companies still rely on century-old cell culture methods to test for microbial contamination—methods that typically take 5 to 28 days to return results.
At MantaBio, we’re building a solution designed for modern manufacturing. Our fully automated system detects microbial contamination in just 2 hours, helping manufacturers reduce downtime, avoid batch loss, and respond quickly when every hour matters. Late-detected contamination events can cost companies $10 million to $100 million per incident, making fast, accurate detection critical to both patient safety and operational success.
We’re grateful to our investors and early partners for their belief in our mission and their support in bringing this technology to market.
MantaBio was co-founded by Dr. Jack Regan, Tom-Forest-Farb Horch, Tim Carr, and Carter Boisfontaine. The company is headquartered in Beverly, Massachusetts.
To learn more or contact our team, please visit www.mantabio.com or email info@Manta-bio.com.